MannKind Appoints Tony Hooper to Its Board of Directors
November 21 2019 - 9:00AM
MannKind Corporation (NASDAQ:MNKD) today announced
that Anthony Hooper will join its Board of Directors, effective
January 1, 2020. Mr. Hooper will also serve as a member of
the Audit Committee of the Board. Mr. Hooper brings 35 years of
experience in the pharmaceutical industry to the MannKind Board of
Directors.
“Tony will be a terrific addition to our board
of directors,” said Kent Kresa, Chairman of the Board of MannKind
Corporation. “His commercial operations experience and his deep
knowledge of the pharmaceutical industry will be invaluable to
MannKind as we look to grow our company for the future.”
Mr. Hooper served as executive vice
president of Global Commercial Operations for Amgen Inc. from Oct
2011 until August 2018. During his tenure, he led the
transformation of Amgen's commercial organization, placing a
relentless focus on putting patients at the center of all the
company’s activities. Under his leadership, Amgen grew
revenue by 50 percent, launched six new first-in-class
medicines for serious diseases, more than doubled the global
footprint by expanding into 50 new countries, and
established a new biosimilars business. Prior to joining
Amgen, Hooper spent more than 15 years at Bristol-Myers Squibb. His
last role there was senior vice president, Global Commercial
Operations and president of the company’s $15 billion
pharmaceutical business in the Americas, Japan and Intercontinental
regions. Previously, he was assistant vice president of Global
Marketing for Wyeth Laboratories and led the international
marketing group for Lederle International. Mr. Hooper earned
law and MBA degrees from the University of South Africa.
The addition of Mr. Hooper will bring the total
number of MannKind Board members to eight.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company’s first
FDA-approved product and the only inhaled rapid-acting mealtime
insulin in the United States, where it is available by prescription
from pharmacies nationwide. MannKind is headquartered in
Westlake Village, California, and has a state-of-the art
manufacturing facility in Danbury, Connecticut. The Company also
employs field sales and medical representatives across the U.S. For
further information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties, including
statements regarding MannKind’s ability to directly commercialize
pharmaceutical products. Words such as “believes”, “anticipates”,
“plans”, “expects”, “intend”, “will”, “goal”, “potential” and
similar expressions are intended to identify forward-looking
statements. These
forward-looking statements are based upon the
MannKind’s current expectations. Actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the ability to
generate significant product sales for MannKind, MannKind’s ability
to manage its existing cash resources or raise additional cash
resources, stock price volatility and other risks detailed in
MannKind’s filings with the Securities and Exchange Commission,
including the Annual Report on Form 10-K for the year ended
December 31, 2018 and subsequent periodic reports on Form 10-Q
and current reports on Form 8-K. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. All forward-looking
statements are qualified in their entirety by this cautionary
statement, and MannKind undertakes no obligation to revise or
update any forward-looking statements to reflect events or
circumstances after the date of this press release.
Company Contact: 818-661-5000
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024